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INTRODUCTION 
Diabetes mellitus (DM) is one of the most common non-
communicable diseases (NCDs) globally. In India, 61.3 
million persons effected with diabetes in 2011 and it will be 
101.2 million by 2030.The number of people with type 2 
diabetes is increasing in every country and is associated with 
significant morbidity and mortality due to cardiovascular 
complications.
1 
There is a recognized need for new treatment options for type 
2 diabetes mellitus (T2DM). There is a move towards 
introducing different classes of anti-diabetic drugs as 
additional therapeutic options with complementary 
mechanisms of existing therapies to achieve and maintain 
better glycemic control. 
 
Only two organs in the human body—the liver and the 
kidney—possess sufficient gluconeogenic enzyme activity 
and glucose-6-phosphatase activity to enable them to release 
glucose into the circulation as a result of gluconeogenesis.
2
 
Normally, the kidneys account for ~ 40% of total 
gluconeogenesis and ~ 20% of all glucose released into the 
circulation in humans.
3
 In contrast to the liver, the kidney 
increases its release of glucose after glucose ingestion, 
potentially contributing to postprandial hyperglycemia in 
diabetic patients. Hypoglycemia promotes renal 
gluconeogenesis by increasing the renal uptake of circulating 
gluconeogenic substrates.
4
 
Patients with type-2 diabetes mellitus have an increase in 
glucose production by as much as 300%, which is equally 
contributed to by hepatic and renal sources.
5
 Plasma glucose 
is neither protein-bound nor complexed with macromolecules 
and is therefore freely filtered at the glomerulus and in normal 
situations almost all of it is reabsorbed in the proximal tubule 
by an insulin-independent process. Patients with diabetes 
mellitus have been shown to experience hyperglycemia 
without resultant glycosuria, and the maximal glucose 
reabsorptive capacity in these patients has been shown to 
increase from a normal level of 352 mg/min (19.5 
mmol/l/min) to 419 mg/ min (23.3mmol/l/min).
6
 This may be 
due to increased expression of glucose transporters at 
proximal tubule in diabetic conditions and probably 
represents a physiological response to increased glucose 
delivery to the proximal tubule that is ultimately 
maladaptive.
7
The transfer of glucose from the tubular lumen 
to the interstitial space is executed by the active process of Na 
dependent glucose transport on the apical membrane to take 
glucose from the lumen to the cell, and facilitated diffusion 
glucose transport on the basolateral membrane to release 
glucose into the interstitium.
7’8
 
Medical researchers were working on anti-diabetic agents that 
can improve glycemic control without increasing 
hypoglycemia while promoting weight loss and improving β-
cell function. 
The US Food and Drug Administration have approved (on 
March 29, 2013) a novel glucose-lowering agent, 
canagliflozin (Invokana, Janssen Pharmaceuticals) for the 
treatment of adults with type 2 diabetes.
9
  Canagliflozin is the 
first in a new class of drug, an oral inhibitor of sodium 
glucose cotransporter 2 (SGLT2). SGLT2, a 672 amino-acid, 
high capacity, low affinity transmembrane protein, is 
expressed primarily in the early proximal renal tubule and is 
responsible for most of the glucose reabsorption in the 
kidneys. Inhibition of SGLT2 decreases glucose reabsorption 
in the renal tubule and increases urinary glucose excretion 
(UGE), with a consequent lowering of plasma glucose levels 
as well as weight loss due to 300-400 kcal/day loss.
10, 11 
Longer-term treatment studies are necessary to determine 
whether the weight loss observed in this study will persist 
beyond the short treatment period examined here. 
Pharmacokinetic characteristics of canagliflozin: 
 Half-life of 11-13 hrs supports once-daily dosing 
 Balanced renal and biliary excretion 
 Glucuronidation is major metabolic pathway 
 No active metabolites 
 No clinically meaningful drug-drug interactions observed 
Dose-ranging trial demonstrates that canagliflozin, a novel 
oral antihyperglycemic agent, at all doses studied, 
significantly improved glycemic control without an increased 
occurrence of hypoglycemia in subjects with type 2 diabetes 
who had inadequate glycemic control with metformin. Studies 
have shown that canagliflozin was associated with significant 
reductions in A1C from baseline (7.6–8.0%) to week 12: -
0.79, -0.76, -0.70, -0.92, and -0.95% for canagliflozin 50, 100, 
200, 300 mg QD and 300 mg BID, respectively, versus -
0.22% for placebo (all P <0.001) and -0.74% for sitagliptin. 
FPG was reduced by -16 to -27 mg/dL, and body weight was 
reduced by-2.3 to-3.4%, with significant increases in urinary 
glucose-to-creatinine ratio.
12 
Despite the modest effect on HbA1c predicted for SGLT2 
inhibitors, the introduction of a novel means of reducing 
hyperglycemia increases the treatment options available to 
physicians for a disease that frequently requires the use of 
multiple agents to achieve control targets. 
Studies have shown that canagliflozin improved a fasting 
indirect measure of β-cell function (HOMA2-%B).
12, 13  
CV risk factor changes with canagliflozin
14
: 
• Changes in fasting lipids 
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– Increases in LDL-C (Smaller increases in non-HDL-C, 
Apo B, LDL particle number) 
– Increases in HDL-C 
– No change in LDL-C/HDL-C ratio 
– Decreases in TG 
• Decreases in systolic and diastolic blood pressure 
• Improved glycemic control 
• Decrease in body weight 
Canagliflozin: Dosing recommendations in patients with Type 
2 diabetes who need improved glycemic control- 
– Starting dose of 100 mg in patients with eGFR <60 
mL/min/1.73m2, loop diuretics, or age ≥75 years 
– If inadequate response in patients started on 100 mg, 
increase to 300 mg dose 
Canagliflozin is a well tolerated drug. The most common side 
effects of canagliflozin are vaginal yeast infection 
(vulvovaginal candidiasis) and urinary tract infection. Genital 
infections were reported in 13–25% of female subjects across 
canagliflozin treatment groups (3–8% of all subjects) and in 
3% of female placebo subjects (2% of all placebo subjects).
12, 
14 
Because canagliflozin is associated with a diuretic effect, it 
can cause a reduction in intravascular volume leading to 
orthostatic or postural hypotension (a sudden fall in blood 
pressure when standing up). This may result in symptoms 
such as dizziness or fainting, and is most common in the first 
three months of therapy. Other side effects are balanitis or 
balanoposthitis, constipation, thirst, polyuria or pollakiuria 
and less common rash/urticaria (< 2%).In Phase 3 studies 
have shown that hypoglycemia in patients on insulin or 
sulphonylurea agent whereas low rate of hypoglycemia in 
studies of subjects not on agents associated with 
hypoglycemia. 
Clinical trials are underway to assess the efficacy and safety 
of other investigational SGLT2 inhibitors like ipragliflozin, 
empagliflozin. Dapagliflozin (Forxiga, Bristol-Myers 
Squibb/AstraZeneca), is already available in Europe since 
November 2012. The FDA denied approval of dapagliflozin 
in January 2012 because of concerns about a cancer signal.
15
 
A third SGLT2 inhibitor, ipragliflozin (Astellas Pharma), has 
been filed for marketing approval in Japan, and a fourth, 
empagliflozin (Eli Lilly/Boehringer Ingelheim), is in phase 3 
trials and has just been filed for approval in the US.
16 
Recovery of glucose from the glomerular filtrate represents an 
important mechanism in maintaining glucose homeostasis and 
represents a novel target for the management of Type2 
diabetes. By promoting an ‘escape’ mechanism for glucose, 
SGLT2 inhibitors introduce a new mode to the control of 
T2DM. The expected favorable safety profile and insulin-
independent mechanism of action appear to support the use of 
SGLT2 inhibitors in combination with other antidiabetic 
drugs. Canagliflozin added onto metformin monotherapy 
provides clinically valuable improvements in glycemic 
control associated with weight loss and low hypoglycemia 
risk.
12
The profile of effective glucose lowering, weight loss, 
improved b-cell function, and low risk of hypoglycemia 
suggest that canagliflozin may be a clinically useful new 
antihyperglycemic agent. 
CANVAS- CANaglifozin Cardiovascular Assessment Study 
which is estimated to primary completion on June 2018 
will assess canagliflozin (JNJ-28431754) in the treatment of 
patients with type 2 diabetes with regard to cardiovascular 
(CV) risk for major adverse cardiac events including CV 
death, heart attack, and stroke in patients with type 2 diabetes, 
whose diabetes is not well controlled at the beginning of the 
study and who have a history of CV events or have a high risk 
for CV events.
17 
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